Therefore, we could not exclude the possibility that RIP1 and/or RIP3 are regulated by Skp2 and responsible for cisplatin resistance in NSCLC cells, and the mechanisms underlying how Skp2 regulates RIP1 and RIP3 need to be further explored. The gene discussed is RIPK3; the disease is non-small cell lung carcinoma.